Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Non Operating Income (2016 - 2020)

Historic Other Non Operating Income for Summit Therapeutics (SMMT) over the last 5 years, with Q1 2020 value amounting to -$3.4 million.

  • Summit Therapeutics' Other Non Operating Income fell 48117.18% to -$3.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$934476.4, marking a year-over-year decrease of 30514.61%. This contributed to the annual value of -$536000.0 for FY2019, which is 11927.36% down from last year.
  • As of Q1 2020, Summit Therapeutics' Other Non Operating Income stood at -$3.4 million, which was down 48117.18% from $899594.3 recorded in Q1 2019.
  • Summit Therapeutics' Other Non Operating Income's 5-year high stood at $1.9 million during Q1 2019, with a 5-year trough of -$3.4 million in Q1 2020.
  • For the 5-year period, Summit Therapeutics' Other Non Operating Income averaged around -$92618.3, with its median value being -$154550.0 (2016).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 92391.88% in 2018, then tumbled by 48117.18% in 2020.
  • Quarter analysis of 5 years shows Summit Therapeutics' Other Non Operating Income stood at -$165000.0 in 2016, then grew by 1.15% to -$163099.9 in 2017, then crashed by 72.77% to -$281788.5 in 2018, then soared by 419.24% to $899594.3 in 2019, then plummeted by 481.17% to -$3.4 million in 2020.
  • Its Other Non Operating Income stands at -$3.4 million for Q1 2020, versus $899594.3 for Q1 2019 and $1.9 million for Q1 2019.